[Comparative changes in hepatic function induced by transhepatic arterial chemoimmunoembolization among liver cancer patients].

H Furukawa; T Hara; T Taniguchi

Home/Archive/PubMed

PubMed · 1444497

[Comparative changes in hepatic function induced by transhepatic arterial chemoimmunoembolization among liver cancer patients].

H Furukawa·T Hara·T Taniguchi

View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Chemoembolization, Therapeutic Hepatic Artery Humans Infusions, Intra-Arterial Liver Liver Cirrhosis Liver Neoplasms Mitomycin Picibanil Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H Furukawa, T Hara, T Taniguchi. 1992. [Comparative changes in hepatic function induced by transhepatic arterial chemoimmunoembolization among liver cancer patients].. https://pubmed.ncbi.nlm.nih.gov/1444497/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update.

Liver metastasis is one of the main problems encountered in colorectal cancer management as the liver is the most common metastatic site. Several treatment options are available, among which transarterial chemotherapy has proved effective in achieving some local tumour control, improving the quality of life through symptomatic control as well as survival time. The present paper is intended to provide an overview of the techniques, indications and results of regional chemotherapy, which comprises transarterial chemoembolization (TACE) and chemoperfusion. This treatment approach has symptomatic, palliative, adjuvant and potentially curative objectives. We reviewed the studies involving TACE and chemoperfusion of colorectal liver metastases during the last few years to update the previous reviews published on this subject. The results achieved were so variable, due to the variations in patient selection criteria and regimens used between the different studies. The median survival ranged from 9 to 62 months and the morphological response ranged from 14 to 76%. Technical aspects, results, and complications of this modality will be demonstrated with a detailed analysis and comments.

Chemoembolization, Therapeutic↗

PubMed2004

[Potentials of interventional radiology: vascular ablations].

Advanced hepatic tumours which can't be treated by either surgically or by percutaneous thermoablation can be cured by intraarterial chemoperfusion, chemoembolization or occlusion of the feeding artery. Occasionally the combination of these methods results in a better and loneer life.

Chemoembolization, Therapeutic↗

PubMed2004

Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization.

Stage 4s neuroblastoma (NB) is a unique entity seen in infants less than 1 year of age, with metastatic disease confined to liver, skin, or bone marrow. Despite metastatic spread, stage 4s NB has a favorable outcome. An exception to this is seen in neonates who present with progressive enlargement of the liver with secondary respiratory compromise and liver failure. We describe a 4-week-old neonate who presented with 4s NB, with a rapidly enlarging liver, resulting in respiratory and hepatic failure, who had a rapid, sustained, and ongoing response to chemoembolization of the hepatic artery. This approach is feasible at this age, and may be effective in improving the outcome in this group of patients.

Chemoembolization, Therapeutic↗